Locally Advanced NSCLC: Finally Progress
August 21, 2018 | Online

Overview

This live session of the IASLC Lung Cancer Grand Rounds webinar series features Dr. Nasser Hanna. Dr. Hanna will address treatment of patients with unresectable or inoperable stage III non-small cell lung cancer (NSCLC). For the past two decades, standard treatment has consisted of chemotherapy and radiation therapy.  No strategies - including utilizing newer chemotherapy agents - escalating radiation dosages, incorporating induction or consolidation chemotherapy, anti-angiogenics or EGFR targeted agents, has improved outcomes over concurrent chemoradiation therapy alone. The incorporation of checkpoint inhibitors in the treatment of patients with stage III NSCLC offers the best hope for significant progress over the last two decades.

Goal & Purpose:

  • Identify and discuss recent data and current clinical research evaluating new approaches to stage III inoperable or unresectable NSCLC
  • Assess those clinical research findings that are most relevant to treating clinicians
  • Appraise the utility of immunotherapy in the management of stage III NSCLC and its potential role in current treatment algorithms

What you should expect to learn

After viewing this program, participants will:

    • Provide an update on scientific progress in the diagnosis, treatment and management of stage III inoperable or unresectable non-small lung cancer (NSCLC)
    • Discuss the incorporation of checkpoint inhibitors into treatment paradigms
    • Identify ongoing clinical trials that are likely to impact patient care in the near future

Contact